Merck & Co. is consolidating around the Street consensus after a strong month, with Wells Fargo lifting its target today and options traders remaining more bullish than their recent habit.
The most active data point this week is on the analyst desk. Wells Fargo raised its target from $145 to $150 this morning, maintaining Overweight — the clearest sign yet that at least one major firm sees more room beyond the current $128.86 price. RBC Capital reiterated Outperform at $142 on the same day. The consensus mean now sits at $131.70, barely $3 above the close, meaning the stock has essentially caught up to the average bull view in just four weeks. The outlier targets tell a wider story: Scotiabank carries $155, Wells Fargo now $150, while Cantor Fitzgerald remains parked at Neutral with a $120 target — below the current price. That split between those who see a re-rating story and those who see a stock already fairly priced will define the next leg. Bulls point to Keytruda's ongoing approval momentum, the Terns acquisition bringing TERN-701 into the pipeline, and the Winrevair PAH opportunity. Bears flag the cost drag from advancing TERN-701, mounting R&D commitments, and healthcare pricing reform risk that could cap earnings multiples.
The valuation picture reinforces the tension. The trailing P/E has settled near 19x, down roughly 3.7 turns over the past month as the re-rating run has partly unwound the growth premium the stock once commanded. EV/EBITDA runs at around 13x, also drifting lower on the 30-day view. Neither multiple is stretched for a large-cap pharma, but the compression is notable: when the stock was at $121, there was a clear gap to close; now the market and the Street are trading near the same number. Factor scores add texture — the dividend rank sits at the 97th percentile and short-score rank at the 77th, while the 30-day EPS momentum factor scores 90, suggesting recent estimate revisions have been firmly positive.
Short interest at 1.2% of free float is too low to be a primary angle here, but it is worth a note. Short interest ticked up roughly 4% on the week — a modest rebuild after a 7% single-day drop on July 7 — consistent with the previous article's observation that short sellers were quietly rebuilding positions while the stock rallied. The borrow market is completely unencumbered: availability is effectively unlimited, with shares-available dwarfing shares-borrowed by an enormous margin. Cost to borrow is less than 0.5%. None of this suggests any squeeze dynamic or crowded positioning; the shorts who are in are doing so cheaply and with no supply constraint.
Options confirm the bullish lean rather than contradict it. The put/call ratio has eased to 0.78, running about one standard deviation below its 20-day average of 0.85 — meaning traders are buying relatively more calls than they have been over the past month. A reading near the low end of the recent range signals that options market participants are not hedging against a near-term pullback. That stands in mild contrast to the modest short-interest rebuild, which is the only bearish signal in the current positioning data, and even that is understated at sub-1.5% of float.
The next fixed catalyst is Q2 earnings on August 4. The last two quarterly prints produced quiet reactions: a 1.1% gain the day after the April 30 report and a 1.8% decline after the May 26 update, with the subsequent five-day moves similarly muted. That pattern — small post-earnings moves in either direction — may set up August 4 as less a binary event and more a moment to assess whether the pipeline narrative around Keytruda and TERN-701 gets incremental confirmation. With the stock trading near consensus and multiples in moderate territory, the question heading into that print is whether the Street will find a reason to move its mean target materially above $132, or whether the current gap compression marks the ceiling of the re-rating story.
See the live data behind this article on ORTEX.
Open MRK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
